In March 2019, the U.S. Food and Drug Administration (FDA) marked a significant milestone in the field  of mental health by granting approval to esketamine nasal spray, marketed as Spravato®, for the  treatment of treatment-resistant depression (TRD) and depressive symptoms in adults with major  depressive disorder (MDD) accompanied by suicidal thoughts or actions. Esketamine, the […]